Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents

Giampaolo Niccoli, Domenico Schiavino, Flavia Belloni, Giuseppe Ferrante, Giuseppe La Torre, Micaela Conte, Nicola Cosentino, Rocco Antonio Montone, Vito Sabato, Francesco Burzotta, Carlo Trani, Antonio Maria Leone, Italo Porto, Maurizio Pieroni, Giampiero Patriarca, Filippo Crea

Research output: Contribution to journalArticle

Abstract

AimsEosinophils have been identified in post-mortem studies as important players of both restenosis and thrombosis after drug-eluting stent (DES) implantation. We aimed at assessing the association between baseline levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, and recurrence of clinical events in a consecutive series of patients who underwent DES implantation.Methods and resultsTwo hundred patients (age 63 ± 10.4, males 75) undergoing implantation of first-generation DES (Taxus or Cypher stents) were enrolled. We measured serum levels of ECP and total IgE by enzyme-linked immunosorbent assay and of C-reactive protein by high-sensitivity nephelometry prior to percutaneous coronary intervention. A clinical follow-up was planned 18 months after discharge. Major adverse cardiac events (MACEs), such as cardiac death, recurrent myocardial infarction, or clinically driven target lesion revascularization, were the endpoint of the study. Twenty-two patients (11) had MACEs and showed higher serum levels of ECP compared with those without MACEs [30.5 (14.4-50) vs. 12.2 (4.4-31) μg/L, P = 0.004]. At simple Cox regression analysis, serum levels of ECP were a significant predictor of MACEs (hazard ratio 1.016, 95 confidence interval 1.003-1.03, P = 0.018).ConclusionThis study shows for the first time an association between baseline ECP levels and the occurrence of MACEs in patients undergoing implantation of DES. Further studies are warranted to establish whether in this setting ECP is a risk marker or plays a contributory pathogenetic role.

Original languageEnglish
Pages (from-to)1340-1347
Number of pages8
JournalEuropean Heart Journal
Volume30
Issue number11
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Eosinophil Cationic Protein
Drug-Eluting Stents
Taxus
Nephelometry and Turbidimetry
Percutaneous Coronary Intervention
Eosinophils
C-Reactive Protein
Immunoglobulin E
Stents
Thrombosis
Enzyme-Linked Immunosorbent Assay
Myocardial Infarction
Regression Analysis
Confidence Intervals
Recurrence

Keywords

  • Drug-eluting stent
  • Eosinophil cationic protein
  • Eosinophils
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. / Niccoli, Giampaolo; Schiavino, Domenico; Belloni, Flavia; Ferrante, Giuseppe; La Torre, Giuseppe; Conte, Micaela; Cosentino, Nicola; Montone, Rocco Antonio; Sabato, Vito; Burzotta, Francesco; Trani, Carlo; Leone, Antonio Maria; Porto, Italo; Pieroni, Maurizio; Patriarca, Giampiero; Crea, Filippo.

In: European Heart Journal, Vol. 30, No. 11, 06.2009, p. 1340-1347.

Research output: Contribution to journalArticle

Niccoli, G, Schiavino, D, Belloni, F, Ferrante, G, La Torre, G, Conte, M, Cosentino, N, Montone, RA, Sabato, V, Burzotta, F, Trani, C, Leone, AM, Porto, I, Pieroni, M, Patriarca, G & Crea, F 2009, 'Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents', European Heart Journal, vol. 30, no. 11, pp. 1340-1347. https://doi.org/10.1093/eurheartj/ehp120
Niccoli, Giampaolo ; Schiavino, Domenico ; Belloni, Flavia ; Ferrante, Giuseppe ; La Torre, Giuseppe ; Conte, Micaela ; Cosentino, Nicola ; Montone, Rocco Antonio ; Sabato, Vito ; Burzotta, Francesco ; Trani, Carlo ; Leone, Antonio Maria ; Porto, Italo ; Pieroni, Maurizio ; Patriarca, Giampiero ; Crea, Filippo. / Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. In: European Heart Journal. 2009 ; Vol. 30, No. 11. pp. 1340-1347.
@article{7da4a6211a7d4b0c93b89fa0a072589f,
title = "Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents",
abstract = "AimsEosinophils have been identified in post-mortem studies as important players of both restenosis and thrombosis after drug-eluting stent (DES) implantation. We aimed at assessing the association between baseline levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, and recurrence of clinical events in a consecutive series of patients who underwent DES implantation.Methods and resultsTwo hundred patients (age 63 ± 10.4, males 75) undergoing implantation of first-generation DES (Taxus or Cypher stents) were enrolled. We measured serum levels of ECP and total IgE by enzyme-linked immunosorbent assay and of C-reactive protein by high-sensitivity nephelometry prior to percutaneous coronary intervention. A clinical follow-up was planned 18 months after discharge. Major adverse cardiac events (MACEs), such as cardiac death, recurrent myocardial infarction, or clinically driven target lesion revascularization, were the endpoint of the study. Twenty-two patients (11) had MACEs and showed higher serum levels of ECP compared with those without MACEs [30.5 (14.4-50) vs. 12.2 (4.4-31) μg/L, P = 0.004]. At simple Cox regression analysis, serum levels of ECP were a significant predictor of MACEs (hazard ratio 1.016, 95 confidence interval 1.003-1.03, P = 0.018).ConclusionThis study shows for the first time an association between baseline ECP levels and the occurrence of MACEs in patients undergoing implantation of DES. Further studies are warranted to establish whether in this setting ECP is a risk marker or plays a contributory pathogenetic role.",
keywords = "Drug-eluting stent, Eosinophil cationic protein, Eosinophils, Prognosis",
author = "Giampaolo Niccoli and Domenico Schiavino and Flavia Belloni and Giuseppe Ferrante and {La Torre}, Giuseppe and Micaela Conte and Nicola Cosentino and Montone, {Rocco Antonio} and Vito Sabato and Francesco Burzotta and Carlo Trani and Leone, {Antonio Maria} and Italo Porto and Maurizio Pieroni and Giampiero Patriarca and Filippo Crea",
year = "2009",
month = "6",
doi = "10.1093/eurheartj/ehp120",
language = "English",
volume = "30",
pages = "1340--1347",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents

AU - Niccoli, Giampaolo

AU - Schiavino, Domenico

AU - Belloni, Flavia

AU - Ferrante, Giuseppe

AU - La Torre, Giuseppe

AU - Conte, Micaela

AU - Cosentino, Nicola

AU - Montone, Rocco Antonio

AU - Sabato, Vito

AU - Burzotta, Francesco

AU - Trani, Carlo

AU - Leone, Antonio Maria

AU - Porto, Italo

AU - Pieroni, Maurizio

AU - Patriarca, Giampiero

AU - Crea, Filippo

PY - 2009/6

Y1 - 2009/6

N2 - AimsEosinophils have been identified in post-mortem studies as important players of both restenosis and thrombosis after drug-eluting stent (DES) implantation. We aimed at assessing the association between baseline levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, and recurrence of clinical events in a consecutive series of patients who underwent DES implantation.Methods and resultsTwo hundred patients (age 63 ± 10.4, males 75) undergoing implantation of first-generation DES (Taxus or Cypher stents) were enrolled. We measured serum levels of ECP and total IgE by enzyme-linked immunosorbent assay and of C-reactive protein by high-sensitivity nephelometry prior to percutaneous coronary intervention. A clinical follow-up was planned 18 months after discharge. Major adverse cardiac events (MACEs), such as cardiac death, recurrent myocardial infarction, or clinically driven target lesion revascularization, were the endpoint of the study. Twenty-two patients (11) had MACEs and showed higher serum levels of ECP compared with those without MACEs [30.5 (14.4-50) vs. 12.2 (4.4-31) μg/L, P = 0.004]. At simple Cox regression analysis, serum levels of ECP were a significant predictor of MACEs (hazard ratio 1.016, 95 confidence interval 1.003-1.03, P = 0.018).ConclusionThis study shows for the first time an association between baseline ECP levels and the occurrence of MACEs in patients undergoing implantation of DES. Further studies are warranted to establish whether in this setting ECP is a risk marker or plays a contributory pathogenetic role.

AB - AimsEosinophils have been identified in post-mortem studies as important players of both restenosis and thrombosis after drug-eluting stent (DES) implantation. We aimed at assessing the association between baseline levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, and recurrence of clinical events in a consecutive series of patients who underwent DES implantation.Methods and resultsTwo hundred patients (age 63 ± 10.4, males 75) undergoing implantation of first-generation DES (Taxus or Cypher stents) were enrolled. We measured serum levels of ECP and total IgE by enzyme-linked immunosorbent assay and of C-reactive protein by high-sensitivity nephelometry prior to percutaneous coronary intervention. A clinical follow-up was planned 18 months after discharge. Major adverse cardiac events (MACEs), such as cardiac death, recurrent myocardial infarction, or clinically driven target lesion revascularization, were the endpoint of the study. Twenty-two patients (11) had MACEs and showed higher serum levels of ECP compared with those without MACEs [30.5 (14.4-50) vs. 12.2 (4.4-31) μg/L, P = 0.004]. At simple Cox regression analysis, serum levels of ECP were a significant predictor of MACEs (hazard ratio 1.016, 95 confidence interval 1.003-1.03, P = 0.018).ConclusionThis study shows for the first time an association between baseline ECP levels and the occurrence of MACEs in patients undergoing implantation of DES. Further studies are warranted to establish whether in this setting ECP is a risk marker or plays a contributory pathogenetic role.

KW - Drug-eluting stent

KW - Eosinophil cationic protein

KW - Eosinophils

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=67651083694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651083694&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehp120

DO - 10.1093/eurheartj/ehp120

M3 - Article

C2 - 19383735

AN - SCOPUS:67651083694

VL - 30

SP - 1340

EP - 1347

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 11

ER -